Section VII. Vascular disease and risk factors

Nephrology Dialysis Transplantation

Volumn 17, Issue SUPPL. 7, 2002, Pages 88-109

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CALCIUM; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FIBRINOGEN; FISH OIL; GEMFIBROZIL; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW MOLECULAR WEIGHT HEPARIN; NICOTINIC ACID; PHOSPHORUS; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET THERAPY; DRUG EFFICACY; DYSLIPIDEMIA; FLUSHING; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HUMAN; HYPERGLYCEMIA; HYPERPHOSPHATEMIA; HYPERTRIGLYCERIDEMIA; LIFESTYLE; LIPID ANALYSIS; LIVER TOXICITY; NUTRITIONAL STATUS; PATHOGENESIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SMOKING HABIT;

HUMANS; RISK ASSESSMENT; RISK FACTORS; VASCULAR DISEASES;

EID: 0036036674     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (328)

1. Causes of death. USRDS. United States Renal Data System
2. The USRDS Dialysis Morbidity and Mortality Study: Wave 2. United States Renal Data System
3. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis
4. Abysmal prognosis of patients with type 2 diabetes entering dialysis./
5. Clinical epidemiology of cardiovascular disease in chronic renal disease
6. The clinical epidemiology of cardiac disease in chronic renal failure
7. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)
8. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension
9. Prevention of coronary heart disease in clinical practice. European recommendations revised and reinforced
10. A prospective comparison of methods for determining if cardiovascular disease is a predictor of mortality in dialysis patients
11. Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis
12. Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease
13. Smoking, blood pressure and serum albumin are major determinants of carotid atherosclerosis in dialysis patients. CREED Investigators. Cardiovascular Risk Extended Evaluation in Dialysis patients
14. Influence of smoking on the survival rate of diabetic patients requiring hemodialysis
15. High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia
16. Association between plasma homocysteine concentration and carotid atherosclerosis in hemodialysis patients
17. Accelerated atherosclerosis in prolonged maintenance hemodialysis
18. Hyperlipidemia in patients with chronic renal disease
19. Prevalence of serum lipid abnormalities in chronic hemodialysis
20. When to treat dyslipidaemia of patients with chronic renal failure on haemodialysis? A need to define specific guidelines
21. Comparison of several atherogenicity indices by the analysis of serum lipoprotein composition in patients with chronic renal failure with or without haemodialysis, and in renal transplant patients
22. Atherogenic lipids and lipoproteins in hemodialysis patients
23. Defective high-density lipoprotein composition in patients on chronic hemodialysis. A possible mechanism for accelerated atherosclerosis
24. High-density lipoprotein cholesterol subfractions in chronic uremia
25. Anomalies in composition of uremic lipoproteins isolated by gradient ultracentrifugation: Relative enrichment of HDL in apolipoprotein C-III at the expense of apolipoprotein A-I
26. Apoprotein A-I and high density lipoprotein subfractions in patients with chronic renal failure receiving hemodialysis
27. Lipoprotein abnormalities in chronic haemodialysis patients
28. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure
29. Lipoprotein heterogeneity in end-stage renal disease
30. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia - Relation to renal function and dialysis
31. Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients
32. Lipoprotein metabolism and renal failure
33. Lipid abnormalities in end stage renal disease
34. Atherogenic lipoprotein phenotype in end-stage renal failure: Origin and extent of small dense low-density lipoprotein formation
35. Non-insulin-dependent diabetes mellitus and hypertriglyceridemia impair lipoprotein metabolism in chronic hemodialysis patients
36. Low-density lipoprotein subfraction profiles in chronic renal failure
37. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis
38. Compositional and functional changes of low-density lipoprotein during hemodialysis in patients with ESRD
39. Apolipoprotein B-containing lipoproteins in renal failure: The relation to mode of dialysis
40. Decreased VLDL apoprotein CII/apoprotein CIII ratio may be seen in both normotriglyceridemic and hypertriglyceridemic patients on chronic hemodialysis treatment
41. Apolipoprotein AI and apolipoprotein B containing particle analysis in normolipidemic hemodialyzed patients: Evidence of free apolipoprotein E
42. Severe defect in clearing postprandial chylomicron remnants in dialysis patients
43. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction
44. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women
45. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subtractions: Relative contribution of small, dense LDL to coronary heart disease risk
46. Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women
47. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
48. The metabolic syndrome, LDL particle size, and atherosclerosis: The Atherosclerosis and Insulin Resistance (AIR) study
49. Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure
50. Postheparin plasma triglyceride lipases in chronic hemodialysis: Evidence for a role for hepatic lipase in lipoprotein metabolism
51. Conjugated diene fatty acids in patients with chronic renal failure: Evidence of increased lipid peroxidation?
52. Plasma lipids are not oxidized during hemodialysis
53. Defect in cholesterol transport in patients receiving maintenance hemodialysis
54. Lecithin: Cholesterol acyltransferase activity in dialyzed and undialyzed chronic uremic patients
55. Lecithin: Cholesterol acyltransferase activity, HDL-cholesterol and apolipoprotein A in serum of patients undergoing chronic haemodialysis
56. Defect in cholesteryl ester transport in serum of patients with uremia receiving maintenance hemodialysis: Increased inhibitor activity for cholesteryl ester transfer
57. Decreased clearance of low-density lipoprotein in uremic patients under dialysis treatment
58. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor
59. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subtraction in healthy subjects
60. Lipoprotein heterogeneity and apolipoprotein B metabolism
61. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans
62. Remnant-like particle cholesterol may indicate atherogenic risk in patients on chronic hemodialysis
63. Increased lipoprotein-remnant formation in chronic renal failure
64. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients
65. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients
66. Peroxidative modification of very-low-density lipoproteins in chronic hemodialysis patients
67. Susceptibility of VLDL to oxidation in patients on regular haemodialysis
68. Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias
69. Cholesterol and lipid disturbances in renal disease: The natural history of uremic dyslipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis
70. Hyperlipoproteinaemia in renal failure: Pathogenesis and perspectives for intervention
71. Lipid abnormalities in maintainance dialysis patients and renal transplant recipients
72. Preliminary screening of the relationship of serum lipids to survival of chronic dialysis patients
73. Factors associated with calcification of the abdominal aorta in hemodialysis patients
74. Cardiovascular risk factors in chronic renal failure and hemodialysis populations
75. Risk factors for cardiovascular disease in end-stage renal failure patients: A 21 year study
76. Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis. Results of a prospective study
77. Fall of cholesterol with time on dialysis: Impact on atherogenicity
78. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients
79. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities
80. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study
81. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons
82. Why are lipids not predictive of cardiovascular death in the dialysis patient?
83. Premature cardiovascular disease in chronic renal failure
84. Cardiovascular disease in patients with chronic renal failure
85. Cholesterol lowering in the elderly population
86. Should we reduce blood cholesterol to prevent cardiovascular disease among patients with chronic renal failure?
87. Should hyperlipidaemia in dialysis patients be treated?
88. Recommendations regarding public screening for measuring blood cholesterol
89. Is the determination of LDL cholesterol according to Friedewald accurate in CAPD and HD patients?
90. Effects of two low-flux cellulose acetate dialysers on plasma lipids and lipoproteins-a cross-over trial
91. Anabolic steroids
92. Secondary causes of hyperlipidemia
93. Nandrolone decanoate reduces serum lipoprotein(a) concentrations in hemodialysis patients
94. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients
95. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials
96. Predictors of mortality in hemodialysis patients
97. Are serum albumin and cholesterol reliable outcome markers in elderly dialysis patients?
98. Serum albumin is a strong predictor of death in chronic dialysis patients
99. Prealbumin-retinol-binding-protein-retinol complex in hemodialysis patients
100. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute
101. Clinical outcomes in statin treatment trials: A meta-analysis
102. Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis
103. Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis
104. Cost-benefit analysis of lipid lowering therapy
105. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S)
106. Lipid-lowering therapy in low-risk patients
107. Association of morbidity with markets of nutrition and inflammation in chronic hemodialysis patients: A prospective study
108. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia
109. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators
110. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators
111. Dietary treatment of hyperlipidemia in chronic hemodialysis patients
112. Dietary polyunsaturated fats of the W-6 and W-3 series reduce postprandial lipoprotein levels. Chronic and acute effects of fat saturation on postprandial lipoprotein metabolism
113. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients
114. Physical activity levels in patients on hemodialysis and healthy sedentary controls
115. Endurance exercise training. An effective therapeutic modality for hemodialysis patients
116. Metabolic effects of exercise training in hemodialysis patients
117. Exercise training reduces coronary risk and effectively rehabilitates hemodialysis patients
118. Altered abdominal fat distribution and its association with the serum lipid profile in non-diabetic haemodialysis patients
119. Body weight-for-height relationships predict mortality in maintenance hemodialysis patients
120. Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients
121. Obesity and mortality in ESRD: Is it good to be fat?
122. European and American recommendations for coronary heart disease prevention
123. Clinical investigation on the hypolipidemic effect of simvastatin versus probucol in hemodialysis patients
124. Lipid-lowering therapy in patients with renal disease
125. Plasma nicotinic acid levels in hemodialysis patients after the administration of niceritrol
126. Effects of the nicotinic acid analogue niceritrol on lipoprotein Lp(a) and coagulation-fibrinolysis status in patients with chronic renal failure on hemodialysis
127. Niceritrol reduces plasma lipoprotein(a) levels in patients undergoing maintenance hemodialysis
128. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients
129. Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure
130. RenaGel, a non-absorbed cal
131. Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis
132. Triglyceride-rich lipoproteins: Are links with atherosclerosis mediated by a procoagulant and proinflammatory phenotype?
133. Calculated low-density lipoprotein cholesterol should not be used for management of lipoprotein abnormalities in patients with diabetes mellitus
134. Additive impacts of diabetes and renal failure on carotid atherosclerosis
135. Acute muscular syndrome associated with administration of clofibrate
136. Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: Pharmacokinetics and effects
137. Effect of bezafibrate on lipoprotein (a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving haemodialysis
138. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
139. The effects of gemfibrozil upon the hypercoagulable state in dyslipidaemic patients with chronic renal failure
140. The effect of renal function on the pharmacokinetics of gemfibrozil
141. Normalization of lipoprotein lipase and hepatic lipase by gemfibrozil results in correction of lipoprotein abnormalities in chronic renal failure
142. Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure
143. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: Assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial
144. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures
145. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids
146. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL
147. Protective effects of high-density lipoprotein against oxidative stress are impaired in haemodialysis patients
148. The effect of renal failure and haemodialysis on the concentration of free apolipoprotein A-1 in serum and the implications for the catabolism of high-density lipoproteins
149. Influence of end-stage renal failure on concentrations of free apolipoprotein A-1 in serum
150. Monocyte expression of tissue factor and adhesion molecules: The link with accelerated coronary artery disease in patients with chronic renal failure
151. Effects of fish oil rich in eicosapentaenoic acid on serum lipid in hyperlipidemic hemodialysis patients
152. Omega-3 polyunsaturated fatty acids in chronic renal insufficiency
153. Results of a long-term administration of omega-3 fatty acids in haemodialysis patients with dyslipoproteinaemia
154. Fish oil modifies lipids and reduces platelet aggregability in haemodialysis patients
155. Effect of n-3 fatty acids from fish oil on hemostasis, blood pressure, and lipid profile of dialysis patients
156. Improvement of plasma lipoprotein profiles during high-flux dialysis
157. Improvement in lipid profiles and triglyceride removal in patients on polyamide membrane hemodialysis
158. High flux dialysis membranes improve plasma lipoprotein profiles in patients with end-stage renal disease
159. High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients
160. Effects of erythropoietin therapy on the lipid profile in end-stage renal failure
161. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study
162. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients
163. Arterial stiffening and vascular calcifications in end-stage renal disease
164. Coronary artery calcifications in children and young adults treated with renal replacement therapy
165. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis
166. Mitral valve calcification as an index of left ventricular dysfunction in patients with end-stage renal disease on peritoneal dialysis
167. Cardiac valve calcification in haemodialysis patients: Role of calcium-phosphate metabolism
168. Why are coronary plaques more malignant in the uraemic patient?
169. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure
170. Arterial calcification and pathology in uremic patients undergoing dialysis
171. Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease
172. Re-evaluation of risks associated with hyperphosphatermia and hyperparathyroidism in dialysis patients: Recommendations for a change in management
173. Managing phosphate retention: Is a change necessary?
174. Hemodiafiltration - A new treatment option for hyperphosphatemia in hemodialysis patients
175. Daily home haemodialysis in The Netherlands: Effects on metabolic control, haemodynamics, and quality of life
176. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis
177. Phosphate kinetics during high-flux hemodialysis
178. Renal osteodystrophy: Management of hyperphosphataemia
179. Lipoprotein(a) in renal disease
180. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies
181. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: Prospective results from the Bruneck study
182. Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a)
183. Lipoprotein(a) levels in chronic renal disease states, dialysis and transplantation
184. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis
185. Apolipoprotein(a) phenotypes and serum lipoprotein(a) levels in maintenance hemodialysis patients with/without diabetes mellitus
186. Serum lipoprotein(a) concentration in patients with chronic renal failure receiving haemodialysis: Influence of apolipoprotein(a) genetic polymorphism
187. Lipoprotein(a) levels in hemodialysis patients: Relation to glucose intolerance and hemodialysis duration
188. Lipoprotein(a) in patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis
189. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients
190. Serum lipoprotein(a) and coronary artery disease in uremic patients on chronic hemodialysis
191. Lipoprotein(a) is a predictor for cardiovascular mortality of hemodialysis patients
192. Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy
193. Serum lipoprotein(a) as an independent cardiovascular risk factor for patients undergoing chronic hemodialysis
194. Lipoprotein (a) in chronic renal failure patients undergoing hemodialysis: Does it have an independent role in the development of further cardiovascular complications?
195. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients
196. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients
197. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: A prospective study in 412 subjects
198. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: A prospective follow-up
199. Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease
200. Lipoprotein (a) concentration and apolipoprotein(a) size: A synergistic role in advanced atherosclerosis?
201. High plasma levels of apo(a) fragments in Caucasians and African-Americans with end-stage renal disease: Implications for plasma Lp(a) assay
202. Increased plasma concentrations of LDL-unbound apo(a) in patients with end-stage renal disease
203. LDL-unbound apolipoprotein(a) and carotid atherosclerosis in hemodialysis patients
204. Atherogenic lipid profile and lipoprotein(a) in relation to serum albumin in haemodialysis patients
205. High lipoprotein (a) levels in chronic hemodialysis patients are closely related to the acute phase reaction
206. Corticotropin-induced reduction of plasma lipoprotein(a) concentrations in healthy individuals and hemodialysis patients: Relation to apolipoprotein(a) size polymorphism
207. Adrenocorticotrophic hormone lowers serum Lp(a) and LDL cholesterol concentrations in hemodialysis patients
208. D-thyroxine reduces lipoprotein(a) serum concentration in dialysis patients
209. Influence of fibrinogen on cardiovascular disease
210. Fibrinogen is an independent marker for thoracic aortic atherosclerosis
211. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature
212. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
213. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease
214. Association of fibrinogen with quantity of coronary artery calcification measured by electron beam computed tomography
215. The apolipoprotein E and beta-fibrinogen G/A-455 gene polymorphisms are associated with ischemic stroke involving large-vessel disease
216. Elevated plasma fibrinogen: Cause or consequence of cardiovascular disease?
217. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study
218. Angiographic assessment of effects of bezatibrate on progression of coronary artery disease in young male postinfarction patients
219. Cardiovascular disease, fibrinogen and the acute phase response: Associations with lipids and blood pressure in patients with chronic renal disease
220. Effect of renal replacement therapy on viscosity in end-stage renal disease patients
221. Erythrocyte sedimentation rate, an underestimated toot in chronic renal failure
222. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients
223. Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: A matched case-control study
224. Survival and predictors of death in dialysed diabetic patients
225. Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease
226. The hemodynamic effect of different ultrafiltration rates in patients with cardiac failure and patients without cardiac failure: Comparison between isolated ultrafiltration and ultrafiltration with dialysis
227. Factor VII coagulant activity (VIIc) and hypercoagulability in chronic renal disease and dialysis: Relationship with dyslipidaemia, inflammation, and factor VII genotype
228. Restenosis after elective coronary balloon angioplasty in patients with end stage renal disease: A case-control study using quantitative coronary angiography
229. Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors
230. Plasma glutathione peroxidase activity is reduced in haemodialysis patients
231. Oxidative stress in haemodialysis
232. Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients
233. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis
234. Preserved antioxidative defense of lipoproteins in renal failure and during hemodialysis
235. Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure
236. Oxidative stress and haemodialysis: Role of inflammation and duration of dialysis treatment
237. Critical evaluation of plasma and LDL oxidant-trapping potential in hemodialysis patients
238. Effect of dialysis on oxidative stress in uraemia
239. 8-Hydroxy-2′-deoxy-guanosine of leukocyte DNA as a marker of oxidative stress in chronic hemodialysis patients
240. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy
241. Oxidative stress during dialysis: Effect on free radical scavenging enzyme (FRSE) activities and glutathione (GSH) concentration in granulocytes
242. Role of cellulosic and noncellulosic membranes in hyperhomocystememia and oxidative stress
243. Haemolipodialysis
244. Vitamin E, lipid profile, and peroxidation in hemodialysis patients
245. Oxidative stress is reduced by the long-term use of vitamin E-coated dialysis filters
246. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy
247. Increased susceptibility of LDL to in vitro oxidation in patients on maintenance hemodialysis: Effects of fish oil and vitamin E administration
248. Effect of alpha-tocopherol on in vitro and in vivo metabolism of low-density lipoproteins in haemodialysis patients
249. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial
250. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
251. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions
252. Detection of NG,NG-dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody
253. Isolation and identification of N-G,N-G- and N-G,N′-G-dimethyl-arginine, N-epsilon-mono-, di-, and trimethyllysine, and glucosylgalact
254. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure
255. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease
256. Indices of activity of the nitric oxide system in hemodialysis patients
257. Asymetric dimethylarginine (ADMA): And endogenous inhibitor of NO synthase is elated to the severity of atherosclerosis and predicts mortality in end-stage renal disease (ESRD)
258. Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease
259. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats
260. Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: Relationship to tissue AGEs
261. Alterations in nonenzymatic biochemistry in uremia: Origin and significance of 'carbonyl stress' in long-term uremic complications
262. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA
263. Low-molecular but not high-molecular advanced glycation end products (AGEs) are removed by high-flux dialysis
264. Advanced glycosylation end products in patients with diabetic nephropathy
265. Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure
266. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients
267. Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease
268. Immunohistochemical study of human advanced glycation end-products (AGE) and growth factors in cardiac tissues of patients on maintenance dialysis and with kidney transplantation
269. Importance of homocysteine, lipoprotein (a) and non-classical cardiovascular risk factors (fibrinogen and advanced glycation end-products) for atherogenesis in uraemic patients
270. Influence of hemodialysis membrane type on pentosidine plasma level, a marker of 'carbonyl stress'
271. Reduction of plasma apolipo protein- B by effective removal of circulating glycation derivatives in uremia
272. Why does carboxymethyllysine (CML), a marker of advanced glycation end products (AGEs) not predict cardiovascular and overall mortality in hemodialysis patients
273. Homocysteine and cardiovascular disease
274. A quantitative assessment of plasma omocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes
275. Serum total homocysteine and coronary heart disease
276. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians
277. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project
278. Homocysteine and ischemic heart disease: Results of a prospective study with implications regarding prevention
279. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study
280. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial
281. Plasma homocysteine levels and mortality in patients with coronary artery disease
282. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease
283. MTHFR association with arteriosclerotic vascular disease?
284. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta-analysis
285. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration
286. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study
287. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations
288. Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients
289. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure
290. Hyperhomocyst(e)inaemia in renal failure - What are the implications?
291. Plasma total homocysteine and hemodialysis access thrombosis: A prospective study
292. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study
293. Prospective study of hyperhomocystememia as an adverse cardiovascular risk factor in end-stage renal disease
294. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients
295. Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease
296. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients
297. Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia
298. Effect of usual doses of folate supplementation on elevated plasma homocyst(e)ine in hemodialysis patients: No difference between 1 and 5 mg daily
299. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients
300. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: Results of the Vienna multicenter study
301. Reversal of hyperhomocyst(e)inaemia in chronic renal failure-is folic or folinic acid the answer?
302. Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy
303. Efficacy of folinic versus folic acid for the correction of hyperhomocysteinemia in hemodialysis patients
304. Rapid communication: L-folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients
305. Short term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementation
306. Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients
307. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients
308. Carotid artery stiffness in patients with end-stage renal disease: No effect of long-term homocysteine-lowering therapy
309. Metabolism of vitamin B6 and its requirement in chronic renal failure
310. Atherosclerosis-an inflammatory disease
311. Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease
312. High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease
313. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses
314. Familial and genetic determinants of systemic markers of inflammation: The NHLBI family heart study
315. What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients?
316. Procalcitonin: A new marker of inflammation in haemodialysis patients?
317. Procalcitonin for accurate detection of infection in haemodialysis
318. Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients
319. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients
320. Acute-phase inflammatory process contributes to malnutrition, anemia, and possibly other abnormalities in dialysis patients
321. Plasminogen activator inhibitor-1 activity in chronic renal disease and dialysis
322. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
323. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients
324. Interleukin-6 production of uraemic haemodialysed patients: Effects of different membranes
325. Effects of dialyser and dialysate on the acute phase reaction in clinical bicarbonate dialysis
326. Effect of the hemodialysis membrane on the inflammatory reaction in vivo
327. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients
328. The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients